Targeting the ACE2 and Apelin Pathways Are Novel Therapies for Heart Failure: Opportunities and Challenges by Kazemi-Bajestani, Seyyed M. R. et al.
Hindawi Publishing Corporation
Cardiology Research and Practice
Volume 2012, Article ID 823193, 11 pages
doi:10.1155/2012/823193
Review Article
TargetingtheACE2and ApelinPathways AreNovel Therapiesfor
Heart Failure: Opportunitiesand Challenges
SeyyedM.R.Kazemi-Bajestani,1,2 Vaibhav B. Patel,1,3 Wang Wang,1,2 andGavinY.Oudit1,2,3
1Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, AB, Canada T6G 2S2
2Department of Physiology, University of Alberta, Edmonton, AB, Canada T6G 2H7
3Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, AB, Canada T6G 2G3
Correspondence should be addressed to Gavin Y. Oudit, gavin.oudit@ualberta.ca
Received 12 December 2011; Accepted 21 February 2012
Academic Editor: Gregory Giamouzis
Copyright © 2012 Seyyed M. R. Kazemi-Bajestani et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Angiotensin-converting enzyme 2 (ACE2)/Ang II/Ang 1–7 and the apelin/APJ are two important peptide systems which exert
diverseeﬀectsonthecardiovascularsystem.ACE2isakeynegativeregulatoroftherenin-angiotensinsystem(RAS)whereitmetab-
olizes angiotensin (Ang) II into Ang 1–7, an endogenous antagonist of Ang II. Both the prolonged activation of RAS and the loss
of ACE2 can be detrimental as they lead to functional deterioration of the heart and progression of cardiac, renal, and vascular dis-
eases.RecombinanthumanACE2inananimalmodelofACE2knockoutmicelowersAngII.Theseinteractionsneutralizethepres-
sor and subpressor pathologic eﬀects of Ang II by producing Ang 1–7 levels in vivo, that might be cardiovascular protective. ACE2
hydrolyzes apelin to Ang II and, therefore, is responsible for the degradation of both peptides. Apelin has emerged as a promising
peptide biomarker of heart failure. The serum level of apelin in cardiovascular diseases tends to be decreased. Apelin is recognized
as an imperative controller of systemic blood pressure and myocardium contractility. Dysregulation of the apelin/APJ system may
be involved in the predisposition to cardiovascular diseases, and enhancing apelin action may have important therapeutic eﬀects.
1.Introduction
Angiotensin-converting enzyme 2 (ACE2)/Ang II/Ang 1–7
and apelin/APJ are two important peptide systems with
diverse and fundamental cardiovascular protective eﬀects
that may prevent or reverse a variety of vascular and cardiac
disorders [1–3]. ACE2 is a monocarboxypeptidase which
eﬀe c t i v e l yp l a y sak e yr o l ea st h ec e n t r a ln e g a t i v er e g u l a t o r
of the renin-angiotensin system (RAS). ACE2 is of particular
interest because it is an essential component of RAS which is
possiblyimplicatedinmetabolizingangiotensin(Ang)IIinto
Ang 1–7 [4]. These interactions counteract the pathologic
eﬀects of Ang II by producing Ang 1–7, that is known to
be cardiovascular protective. Ang II impairs cardiovascular
function and enhances pressor and subpressor pathologic
consequences, and hence Ang 1–7 protects against these
pathological processes [1, 2].
Apelin is an endogenous peptide that is widely expressed
in various organs as a 77 amino acid preproapelin. Several
active fragments of apelin have been known (apelin-36,
apelin-19, apelin-17, apelin-16, apelin-13, and apelin-12)
whichrelativelysharesimilarbiologicalactivities.Inaddition
to the possibility of application of apelin as a heart failure
(HF) biomarker, apelin also has direct biological eﬀects
including vasodilatory and inotropic eﬀects [5]. Several
previous studies have shown the cardioprotective eﬀect of
ACE2 and apelin in all three steps of primary, secondary and
tertiary prevention of HF (Figures 1 and 2). In this paper we
summarize the current literature regarding the cardiovascu-
lar eﬀects of ACE2 and apelin and their possible therapeutic
applications.
2. Role of ACE2andApelininSystemicand
Pulmonary Hypertension
Several previous studies demonstrated that ACE2 can mod-
ulate blood pressure. Daily infusion of recombinant human2 Cardiology Research and Practice
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Figure 1: The enzymatic cascade involved in the renin-angiotensin system, key receptor systems, and the biological eﬀects mediated
by Ang II and Ang 1–7. Solid black lines, enzymatic pathways; Broken lines, peptide agonist interacting with its key receptor; Green
arrow, stimulatory eﬀects; Red arrow, pathologic eﬀects; Green bars; inhibitory eﬀects. ACE2: angiotensin-converting enzyme; Akt: protein
kinase B; Ang: angiotensin; APA: aminopeptidase A; AT1R Ang II type 1 receptor; CHOP: CCAAT/enhancer binding protein homologous
protein; Cox-2: cyclooxygenase-2; CPA: carboxypeptidase A; eNOS: endothelial synthase; ERK: extracellular signal-regulated kinase; GRP-
78: glucose regulated protein; IL-6: interleukin-6; JAK-STAT: Janus Kinase- signal transducer and activator of transcription system; JNK:
C-jun-N-terminal kinase; MAPK: mitogen activated protein kinase; Mas R: Ang 1–7 receptor; MCP-1: monocyte cheomattractant protein 1;
MMIF: macrophage migration inhibitory factor; MMP: matrix metalloproteinase; NADPH: nicotinamide adenine dinucleotide phosphate;
NEP: neutral endopeptidase; NF-kappaB: nuclear factor kappa-light-chain-enhancer of activated B cells; NO: nitric oxide; PCP: prolyl
carboxypeptidase(alsoknownasangiotensinaseC);PEP:prolylendopeptidase;PI3K:phosphatidylinositol3-kinases;PKC:proteinkinaseC;
ROS: reactive oxygen species; SOD: superoxide dismutase; TGFβ1, transforming growth factorβ1; TNF α: tumor necrosis factor α;V C A M - 1 :
vascular cell adhesion molecule-1.
ACE2(rhACE2)(2mg/kg−1/d−1)reducestheAngII-induced
hypertension in mice, by reducing Ang II-mediated activa-
tion of enhanced extracellular signal-regulated kinase 1/2
(ERK1/2), protein kinase C (PKC) pathways and renal
ﬁbrosis [6]. It is suggested that ACE2 expression is decreased
in the spontaneously hypertensive rats before the marked
onset of hypertension [7]. It is believed that impaired renal
level of ACE2 contributes to hypertension in humans [8].
Exposureofculturedhumanumbilicalarterysmoothmuscle
cells (HUASMCs) to Ang II results in a signiﬁcant increase
in the mRNA and protein expression of proﬁlin-1, recently
linked to cytoskeleton remodeling by activation of the hyper-
trophic signaling through mitogen activated protein kinase
(MAPK), ERK1/2 and C-jun-N-terminal kinase (JNK), in
conjunction with reduced ACE2 activity [9]. Enhanced
proﬁlin-1 expression and MAPK signaling in HUASMCs in
response to Ang II was noticeably reduced by rhACE2 in
an Ang 1–7-dependent manner [9]. Improvement of ACE2Cardiology Research and Practice 3
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Figure 2: Diverse eﬀects of apelin on cardiovascular system. Black arrows, eﬀects of apelin on various targets; Green arrows and red bars,
favorable stimulatory and inhibitory eﬀects of apelin on cardiovascular system respectively; AAA: abdominal aorta aneurysm; AF: atrial
ﬁbrillation; Akt: protein kinase B; AMPK: adenosine monophosphate-activated protein kinase; BMP: bone morphogenetic protein; CHOP:
CCAAT/enhancer binding protein homologous protein; eNOS: endothelial synthase; hs-CRP: high sensitivity C-reactive protein; ER-stress:
endoplasmic reticulum stress; ERK: extracellular signal-regulated kinase; HTN: hypertension; I/R: ischemia reperfusion; IL-6: interleukin
6; JNK: C-jun-N-terminal kinase; MCSF: macrophage colony stimulating factor; MCP-1: monocyte cheomattractant protein 1; NADPH:
nicotinamide adenine dinucleotide phosphate; NO: nitric oxide; PAH: pulmonary arterial hypertension; PI3K: phosphatidylinositol 3-
kinases; PKC:protein kinase C; PLC: Phospholipase-C; ROS: reactive oxygen species; SOD: superoxide dismutase; TNFα: tumor necrosis
factor.
expression and reduced proﬁlin-1 levels were associated with
an overt suppression of ERK1/2 and JNK phosphorylation in
aortas of spontaneously hypertensive rats [9].
ACE2 overexpression results in increased expression of
various antihypertensive components of the RAS including
Ang 1–7/Mas and AT2R. Vascular transgenic overexpression
of ACE2 results in reduction of arterial blood pressure [10,
11] and an attenuated response to Ang II infusion [10].
Central nervous system overexpression of ACE2 also was
proved to be protective against Ang II induced hypertension
[12].Wysockietal.(2010)showedthatacuteAngIIinfusion-
induced hypertension can be prevented by rhACE2 pre-
treatment (2hrs before the Ang II infusion) in mice. This
antihypertensive eﬀect of rhACE2 was associated with a
decrease in plasma Ang II and increases in plasma Ang 1–7
levels. However, the antihypertensive eﬀect of rhACE2 was
shown to be independent of Ang 1–7 in this study [13].
Wysocki et al. concluded that circulatory decrease of Ang II
was the driving cause of decreased hypertension, rather than
increased levels of Ang 1–7 [13]. This acute antihypertensive
eﬀect of ACE2 seems promising for management of the
patients with hypertension.
Reduced circulating levels of apelin have been demon-
strated in the patients with essential hypertension [14, 15].
Genetic variation in apelin likely contributes to essential hy-
pertension and the onset of aged hypertension [16]. Tate-
moto et al. (2001) showed that arterial pressure after the
administration of apelin-12, apelin-13, and apelin-36 at a
d o s eo f1 0n m o l / k gr e s u l t e di nar e d u c t i o ni na r t e r i a lb l o o d
pressure [17]. Cheng et al. (2003) examined dose response
curves of apelin (10, 20, and 40 nmol/kg) in rats and
concluded that apelin is an arterial and venous dilator in vivo
[18]. Japp et al. (2008) showed nitric oxide (NO)-dependent
vasodilatory eﬀect of apelin in 24 healthy volunteers in vivo
[19]. However, the long-term eﬀects of manipulating the
apelinpathwayanditseﬀectonbloodpressureareunknown.
Several studies focused on the role of ACE2 and apelin
in amelioration of pulmonary arterial hypertension (PAH).
Ang II is of fundamental importance to development and
progression of PAH, due to its vasoconstrictive, ﬁbrotic, and
proliferative eﬀects [20]. Left ventricular failure/remodeling
is one of the frequent consequences of PAH which may
aggravate the global function of the heart. The ability of
ACE2 to combat the ﬁbrosis/proliferative eﬀects of Ang II on
lung and right ventricle (RV) supported the beneﬁcial role
of ACE2 in PAH treatment [20]. ACE2 overexpression [21]
and ACE2 activation by 1-[(2-dimethylamino) ethylamino]-
4-(hydroxymethyl)-7-[(4-methylphenyl) sulfonyl oxy]-9H-
xanthene-9-one (XNT) [22] ameliorate RV systolic failure,
decrease the adverse eﬀects of Ang II, and attenuate pro-
inﬂammatory cytokines in PAH mice. There is promising
evidence of rhACE2 on improvement of RV load-stress
(pulmonary artery banded (PAB)) of early HF [23]. rhACE2
administered to PAB mice for two weeks prevented load-
induced RV systolic and diastolic dysfunction [23]. The
exceptional increasing eﬀe c to fr h A C E 2o nR V[ 23] shows4 Cardiology Research and Practice
the remarkable property of ACE2 for potentially complex
patients with isolated RVHF.
Apelin/APJ is highly expressed in pulmonary vasculature
[24]. Chandra et al. (2011) reported signiﬁcantly lower se-
rum apelin levels in patients with PAH compared to control
subjects [25]. Apelin expression also decreases in the pul-
monary endothelial cells of the patients with PAH [26].
It was shown that PAH in mice may originate from the
disruptionofapelinsignalingwhichismediatedbydecreased
activation of adenosine monophosphate-activated protein
kinase and endothelial synthase (eNOS) [25]. Pyr-Apelin-
13 treatment has been reported to downregulate Ang II
and endothelin-1 and could therefore attenuate RV hyper-
trophy and diastolic dysfunction in rats with PAH [27].
Alastalo et al. (2011) have elegantly shown that apelin could
have both autocrine and paracrine eﬀects against PAH in
pulmonary vasculature [26]. Bone morphogenetic protein-
mediated apelin autocrine production results in enhanced
pulmonary arterial endothelial survival, proliferation, and
migration which can protect the vasculature against PAH.
Importantly, apelin autocrine function against PAH is based
onattenuationofthepulmonaryarterialsmoothmusclecells
response to growth factors and by promoting apoptosis [26].
3. Role of ACE2andApelininDiabetes(DM)
andDiabeticCardiovascularComplications
Attenuation of Ang II-induced glomerular mesangial cell
proliferation, oxidative stress, and collagen IV protein syn-
thesis is thought to be the critical steps in ACE2-related
protection of diabetic nephropathy [28, 29]. Even in non-
diabetic mice loss of ACE2 contributes to increase in renal
lipid peroxidation product formation and activation of
MAPK and ERK 1/2 in glomeruli [30]. ACE2 mRNA has
been shown to be reduced by more than half in both the
glomeruli and proximal tubules of the diabetic patients
compared to controls [31]. ACE2 treatment is believed to be
critical in protection against diabetes induced nephropathy.
rhACE2 treatment attenuated high glucose in cultured
primary rat mesangial cells [32]. The potential role of Ang
II in the induction of kidney injury in ACE2 knocked out
mice has been reported [33]. In addition to the possibility of
renal protective role of rhACE2 due to its antihypertensive
eﬀect in diabetic subjects, rhACE2 also attenuates diabetic
nephropathy via blockade of Ang II-induced nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase activity
in mesangial cells [32]. Bindom et al. (2010) have elegantly
shown that ACE2 gene therapy in mice results in reduced
fasting blood glucose and glucose tolerance improvement
in a diabetic mice model [34]. They also proved that
ACE2 overexpression in diabetic mice signiﬁcantly reduces
apoptosis which can be prevented by Ang 1–7 receptor
blockade [34], further supporting the link between ACE2
and diabetic glycemic control [34, 35].
Severalstudies haveshown anassociation between apelin
levels and overt diabetes [36]. Erdem et al. (2008) demon-
strated that plasma apelin was lower in newly diagnosed
and untreated patients with DM II compared to healthy
controls [37]. Soriguer et al. (2009) showed the association
between apelin levels and glucose concentrations and insulin
sensitivity in diabetic patients suggesting the role of apelin
in diabetes pathogenesis [38]. Furthermore, diabetic mice
exhibited downregulation of apelin receptors and depressed
aortic vascular tone [39]. However, Rittig et al. (2011)
examined the association between apelin and atherosclerosis
indicators (intima media thickness) in 344 subjects with an
increased risk for DM II and did not show any association to
diabetes risk pattern [40].
The eﬀect of apelin in DM control has been shown
in some animal studies. Intracerebroventricular injection of
apelin in mice leads to improved glucose homeostasis
via NO-dependent pathway [41]. Injection of apelin-13
(400pmol/kg) for 10 weeks considerably reduced the pan-
creas endoplasmic reticulum (ER) stress in Akita mice, a
model of DM I, which leads to modiﬁcation of pancreatic
isletmassreductionandpreservationofinsulincontent[42].
This important eﬀect of apelin-13 in type 1 diabetes was
mediated by inhibition of inositol requiring enzyme 1-α and
JNK pathways, suggesting apelin eﬀects on two important
pathways of ER stress and cell death, respectively [42]. In
mice with metabolic syndrome, apelin restores glucose toler-
ance and increases glucose utilization [43]. Apelin treatment
has a favorable eﬀect on vascular function in diabetic mice.
Apelin treatment remarkably adjusts the abnormal aortic
vascular reactivity in response to Ang II and acetylcholine
in DM II mice by increasing the phosphorylation of Akt
and eNOS [39]. Apelin may improve the glycemic status and
insulin sensitivity of the patients and also can ameliorate
vascular functions of diabetic patients.
4. Role of ACE2andApelininVascular
Inﬂammation and Atherosclerosis
Theeﬀectofvascularinﬂammationintheinitiationandpro-
gression of atherosclerosis/cardiovascular diseases has been
well recognized. Gene transfer of ACE2 suppresses the ex-
pression of macrophage migration inhibitory factor, a proin-
ﬂammatory cytokine associated with insulin resistance, in
endothelial cells stimulated by Ang II [44]. ACE2 deﬁciency
contributes to enhanced atherosclerotic plaque formation
and also increases proinﬂammatory cytokines, including
interleukin-6 (IL-6), monocyte chemoattractant protein-1
(MCP-1), and vascular cell adhesion molecule-1, which
deﬁnedthekeyroleofACE2inmodulationofinﬂammation-
dependent atherosclerosis development [44]. Remarkable
eﬀects of rhACE2 on attenuation of Ang II-induced T-
lymphocyte-mediated inﬂammation can be considered as an
evidence for antiinﬂammatory/anti-atherosclerotic eﬀects of
ACE2 [45].
ACE2reducedatherosclerosisprogressioninapolipopro-
tein E knockout mice probably by inhibition of reactive
oxygen species (ROS) subsequent activities [46]. Association
between ACE2 antiatherosclerotic eﬀects and disturbance
of Ang II/Ang 1–7 peptides has been proved [47]. Zhang
et al. (2010) suggested the downregulation of the ERK-p38,
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system (JAK-STAT), and Ang II-induced ROS-nuclear factor
kappa light chain enhancer of activated B cells (NF-kappaB)
signaling pathways and upregulation of the phosphatidyli-
nositol 3 kinases-protein kinase B (PI3K-Akt) pathway
subsequent to ACE2 therapy in rabbits [48]. It has been
shown that overexpression of ACE2 can readily stabilize the
atherosclerotic plaques probably due to protective eﬀects of
Ang 1–7 [49]. Hence we concluded that ACE2 is essential
to prevent or delay the development of atherosclerosis.
The plaque stabilizing eﬀect of ACE2 seems promising for
prevention of acute coronary syndromes (ACS).
Plasma levels of apelin inversely correlated to inﬂamma-
tory markers (C-reactive protein and IL-6) in hemodialysis
patients [50]. Apelin treatment in mice models of abdom-
inal aorta aneurysm (AAA) clearly demonstrated its anti-
inﬂammatory eﬀects that could attenuate AAA formation
[51]. Injected apelin can reduce the mRNA levels of pro-
inﬂammatory markers (MCP-1, macrophage inﬂammatory
protein-1α, IL6 and tumor necrosis factor-α)[ 51]. Apelin
attenuates ultraviolet B-induced edema and inﬂammation
in mice and play an important role in stabilization of the
tissue [52]. Apelin exerts acute anti-inﬂammatory eﬀects on
the vascular system; the results are promising and if these
results can be extrapolated in chronic models, it can be a
proper therapeutic modality for prevention of inﬂammation
in the process of atherosclerosis. Pitkin et al. (2010) have
shown an increase in apelin expression in atherosclerotic
coronary artery, with the additional peptide localizing to
the atherosclerotic plaque [53]. Apelin receptor was also
found to be present within the atherosclerotic plaque and
to have a similar distribution to its ligand [53]. Increased
content of apelin and its receptor might be an indicator
of increased anti-inﬂammatory activation of macrophages
thereby limiting plaque instability. Due to lack of data and
contradictory ﬁndings, the exact role of apelin on atheroscle-
rosis plaque remains inconclusive.
5. Role of ACE2andApelininAngiogenesis
The association between ACE2 and cardiac angiogenesis
during the HF process has not been studied. A few studies
in the cancer ﬁeld have supported an important role of ACE2
in angiogenesis [54, 55]. The probable adverse antiangiogic
eﬀects of ACE2 in HF remain unclear. Apelin angiogenenic
eﬀectshavebeenprovedinfewanimalstudies;howevernone
of the studies targeted the eﬀect of apelin on heart angiogen-
esis.Tianietal.(2009)showedtheremarkableeﬀectofapelin
on portosystemic collateralization and splanchnic neovas-
cularization in portal hypertensive rats [56]. Treatment of
human umbilical vein endothelial cells with apelin dose-
dependently augments angiogenic responses [57]. Kidoya
et al. (2010) indicated that apelin together with vascular
endothelial growth factor (VEGF) eﬃciently induced func-
tional vessels larger than with VEGF alone, in the hind limb
ischemia model of mice [58]. Apelin is required factor for
hypoxia-induced retinal angiogenesis in mice [59]. Available
data imply that apelin is an eﬀective factor in angiogenesis;
however none of the studies have targeted coronary vessels to
test the eﬀect of apelin on their angiogenesis. If the eﬀect of
apelin on cardiac collateralization is proved in future studies,
it can be considered as a valuable factor for the patients with
HF, in particular ischemic HF. The probable oﬀ-or on-target
eﬀects of apelin on other organs angiogenesis, for example,
retinal neovascularization/angiogenesis make interpretation
problematic.
6. Role of ACE2 and Apelin in Post-Myocardial
Infarction (MI) Remodeling
Post-MI remodeling and coronary artery disease are now the
most common cause of HF [60]. In ACE2 deﬁcient mice,
MI leads to enhanced activation of the RAS resulting in
increased cardiac mortality, adverse ventricular remodeling,
and aggravated systolic function [61]. ACE2 contributes
to generation of myocardial Ang 1–7 after MI which may
protect the heart from ischemic consequences [61]. Loss of
ACE2 in post-MI mice is associated with increased Ang II
levels and ROS production. This is followed by increased
matrix metalloproteinase (MMP) activation, inﬂammation,
and activation of MAPK in ACE2-deﬁcient hearts [61]. Der
Sarkissian et al. (2008) analyzed the rats that received an
intracardiac injection of lentivirus containing ACE2 cDNA
followed by coronary artery ligation and found the ischemic
protection of myocardium by ACE2 24 hours after the
ischemic event compared to the control mice [62]. The eﬀect
of ACE2 overexpression on attenuation of left ventricular
ﬁbrosis/remodelingandsystolicfunctionwasalsoshownone
month after MI [63].
Ang II antagonist infusion for 28 days after MI results
in augmented ACE2 cardiac mRNA in normotensive rats,
which may be related to direct blockade of AT1R or the
probable contribution of increased Ang 1–7 [64]. Attenuated
cardiac hypertrophy and improved ventricular contractility
both were chronic antiremodeling eﬀects of ACE2 on ACS-
induced ischemia [64]. Treatment of the rats for a same
period (28 days) with C16, a selective non-peptidic ACE2
inhibitor, at a dose that inhibited myocardial ACE2 activity
was associated with a signiﬁcant increase in MI infarct size
[65]. It seems that acute and long-term eﬀects of ACE2 limits
the infract size following ACS. ACE2 is capable to produce
Ang 1–9 from Ang I [4]. Ocaranza et al. (2010) proved the
eﬃcacy of Ang 1–9 in attenuation of post-MI remodeling
[66]. Further studies are needed to evaluate the eﬀect of
ACE2 on Ang 1–9 increase and its remodeling-attenuation
in coronary artery disease.
Decreased levels of apelin-36 during 5 days interval
following ST elevation MI have been reported [67, 68]. Weir
et al. (2009) also conﬁrmed depressed level of apelin early
after MI. They showed signiﬁcant increase of apelin from
base line to 24 weeks after MI [69]. None of these studies
found any relation between apelin levels and left ventricular
function [67–69]. Kadoglou et al. (2010) showed that both
groups of patients with unstable angina and acute MI had
signiﬁcantly lower level of apelin compared to the patients
with asymptomatic coronary artery disease [70]. According
to our knowledge, only decreased levels of apelin after6 Cardiology Research and Practice
ACS have been proved without any relation with structural
dysfunction of the heart. The therapeutic eﬀect of apelin
in the management of patients with ACS has not been
examined. Evaluation of apelin role before and after acute
events and its role in plaque stabilization seems to be
complicated in animals, as there is no model of unstable
atherosclerotic plaque-induced ACS.
The precise role of ACE2 in protection of the heart
and kidney against ischemia-reperfusion (I/R) injury has
not been elucidated. However, according to the association
between ACE2 and MAPK [61], ACE2 protective eﬀects
against I/R injury seem probable. Simpkin et al. (2007) for
the ﬁrst time demonstrated the protective eﬀects of apelin
against I/R injury in rodents through the reperfusion injury
salvage kinase (RISK) pathway activation [71]. In murine
Langendorﬀ model of I/R injury, apelin-13 could increase
Akt and ERK1/2 phosphorylation as well as increase Akt
activity at 5 and 10min of reperfusion [72]. Activation
of Akt and ERK1/2, two important members of RISK
pathway, can potentially protect the heart against I/R injury
[72]. Administration of apelin can partly block the ER
stress-dependent apoptosis activation in rat models of I/R
injury at 2h of reperfusion which results in the heart
protection against I/R injury [72]. This protection against
I/R injury remained signiﬁcant during time-related changes
at 24h of reperfusion [72]. Administration of apelin (30
pM) in Langendorﬀ model of perfused isolated rat hearts
favorably preserves the impaired cardiac function [73]. In rat
cultured cardiomyocytes, the antioxidant activity of apelin is
thought to be largely due to inhibition of ROS production,
malonaldehyde activity and lactate dehydrogenase leakage
and also activation of superoxide dismutase [73]. According
to several previous investigations, apelin can considerably
protect the heart against I/R injury. However, apelin eﬀects
against I/R injury have not been tested in humans. This
promising eﬀe c to fa p e l i nc a nb ea p p l i e di nh u m a n si nt h e
conditions that I/R injury can impair the heart function
and might be a leading cause of HF. Application of apelin
duringthepercutaneouscoronaryinterventionandcoronary
artery bypass graft immediately and in early days after the
procedure may have therapeutic beneﬁts.
7. Role of ACE2andApelininArrhythmias
Atrial ﬁbrillation (AF) is one of the most common arrhyth-
miasamongthepatientswithcardiovasculardiseases.Down-
regulation of both the mRNA and protein level of ACE2 has
been shown to be associated with the development of AF in
a rapid pacing-induced model [74]. They also showed higher
expression of ERK1/2 cascade and also increased expression
of collagen I protein in the atrial tissues with AF that is
related to increased local Ang II [74]. It could be concluded
that ACE2 treatment can easily protect the heart against
the AF complications including ﬁbrosis and remodeling.
However the results of Donoghue et al. paper (2003) seem
contradictory [75]. Donoghue et al. (2003) reported that
ACE2 overexpression in the heart leads to probable gap
junction remodeling, resulting in severe electrophysiological
disturbances (sustained ventricular tachycardia and terminal
ventricular ﬁbrillation) and high incidence of sudden death
in transgenic mice [75]. The results of Donoghue et al.
has not been conﬁrmed again by other studies, and several
investigations have used ACE2 transgenic mice without
increased sudden cardiac death.
Serum apelin levels are lower in the patients with AF
comparedtocontrols[76,77].Falconeetal.(2010)measured
apelin in 93 patients with persistent AF before successful
external electrical conversion. Patients with apelin levels
below the median showed a hazard ratio of 3.1 of arrhythmia
recurrence compared to those with high apelin levels [78].
Low plasma apelin is an independent prognostic factor for
arrhythmia recurrence in the patients with AF under antiar-
rhythmia medication [78]. Apelin, due to its eﬀect on the
propagation of action potential and contractility in cardiom-
yocytes, is thought to modulate the pathophysiology of AF
[79].Apelinincreasessarcomereshorteninginnormalaswell
as failing cardiomyocytes [79]. Moreover, apelin augments
conduction velocity in monolayers of cultured neonatal rat
cardiac myocytes [79]. According to our knowledge, the level
of apelin has been investigated only in the patients with AF,
and other forms of arrhythmia have not been investigated.
8. Role of ACE2andApelin in HF:
Therapeutic Potentials
The relationship between ACE2 deﬁciency and failure of
heart function including pathological hypertrophy, ventricu-
lar remodeling, and systolic dysfunction is well described [6,
80, 81]. In ACE2 deﬁcient mice model of pressure overload,
increased Ang II leads to severe cardiac hypertrophy [80, 82],
increased activity of MAPK [82], activation of the NADPH
oxidase system and oxidative stress-induced augmented
MMP-mediated degradation of the extracellular matrix
[80]. rhACE2 has antiﬁbrosis properties and may attenuate
expression of Ang II-induced procollagen, transforming
growth factor-β1 ,a n dﬁ b r o n e c t i n[ 6]. The attenuating eﬀect
of rhACE2 on systolic and diastolic dysfunction [6, 81]i s
thought to be largely due to Ang II inhibition [6]. rhACE2
treatment blocks the Ang II-mediated activation of PKC-
α,P K C - β1, ERK 1/2 and JAK-STAT in wild-type mice [6].
Ferreira et al. (2011) showed that chronic XNT infusion,
an ACE2 activator, was associated with decreased cardiac
collagencontent,increasedcardiacAng1–7immunostaining
and a reduction in ERK phosphorylation [83]. Ang 1–9, a
known product of ACE2 activity in RAS, results in consider-
able reduced hypertension-induced cardiac ﬁbrosis through
modulation of collagen I expression [84]. Furthermore, Ang
1–9 attenuates Ang II-inducfed cardiomyocyte hypertrophy
[85]. ACE2 by inhibiting several remodeling pathways can
attenuate Ang II and pressure-overload-induced cardiomy-
opathy.
In HF there is hyperactivity of the sympathetic nervous
system which chronically may have adverse eﬀect on cardiac
function. ACE2, Ang 1–7, and the Mas receptor exist in the
brain; however, controversy remains over their relation with
the cardiovascular functions [86]. There is growing interestCardiology Research and Practice 7
in the application of ACE2 in central nervous system. Xiao
etal.(2011)showedthatcentralACE2overexpressionapplies
a considerable cardiac protective eﬀect in the mice model
of HF which was associated with a signiﬁcant decrease in
sympathetic biomarkers [87]. Brain selective human ACE2
over expression also showed to be eﬀective for management
of hypertension in transgenic mice [88]. Direct eﬀects of
central ACE2 treatment on HF improvement and also its role
in hypertension attenuation are both acceptable evidence for
the eﬃcacy of ACE2 on HF management.
Arrhythmia also may occur in the patients with HF
and can worsen the structural and functional status of the
heart in these patients. The protective eﬀect of ACE2 against
arrhythmia in the failed heart is a subject of debate. The
importance of the balance between ACE-Ang II-AT1R axis
and the ACE2-Ang 1–7-Mas receptor axis in the regulation
o fh e a r tc e l lv o l u m eh a sb e e ns u g g e s t e d[ 89]. The key role of
Ang1–7indecreasingthecellvolumewhichresultsindecline
in activation of swelling-activated chloride current (IClswell)
suggesting a likely contribution of ACE2 in prevention of
major post-ischemic cardiac arrhythmias [89]. However, De
Mello (2009) mentioned the probable eﬀect of overexpressed
ACE2 on generation of early afterdepolarization especially
in the patients with HF [90]. Regarding the probable
arrhythmogenic eﬀects of ACE2 in the patients with HF, it
seems that precise dose adjustment based on the severity of
HF may prevent this side eﬀect.
There is growing interest regarding the protective role
of apelin in HF development. Apelin level is considerably
reduced in the patients with HF [91–93]. Several studies
showed high expression of apelin/APJ in the heart and in
vascular systems of rodents and humans [24, 93, 94]. The
mechanisms by apelin reduction causes HF are becoming
clearer. Gao et al. (2009) reported signiﬁcant increase of
apelinasanindicator ofimproved cardiacfunctionfrom3to
21 days after bone marrow mononuclear cell transplantation
in the patients with HF through autocrine and paracrine
mechanisms[92].Apelinreducesleftventricularpreloadand
afterload in rodents [95] and is known to be a strong positive
inotropic agent [53, 94, 96] that could be outstandingly
helpful in treatment of HF. Apelin mutant mice develop HF
associated with aging and pressure overload [97]. Infusion
of apelin-13 [98] and apelin-12 [99] enhances myocardial
function of the left anterior descending artery ligation model
of HF in rats. Perfusion of isolated rat hearts with apelin-
16 caused an inotropic eﬀect with a similar time course to
endothelin-1 [94]. Interestingly, apelin can present a grad-
ually developing but sustained inotropic eﬀect [94], which
is a signiﬁcant diﬀerence compared to classical β-adrenergic
eﬀects. Apelin administration to the rats in ischemic HF sig-
niﬁcantly attenuates diastolic dysfunction [96]. The involve-
ment of phospholipase-C, PKC, Na+/H+ and Na+/Ca2+
pumps has been proved in positive inotropic eﬀects of
apelin [94, 100, 101]. The interaction between apelin and
two important regulatory pumps has been proposed to
be contributed to increased inotropic eﬀects of apelin by
restoration of calcium in the cardiomyocyte cytosol.
Japp et al. (2010) investigated the acute cardiovascular
eﬀect of intrabrachial infusion of (Pyr (1)) apelin-13 in the
patients with chronic HF and healthy volunteers and found
vasodilatation in patients and control subjects [102]. Sys-
temic infusions of (Pyr(1)) apelin-13 (30 to 300nmol/min)
result in elevated cardiac index, lowered mean arterial
pressure and peripheral vascular resistance in HF patients
and healthy control subjects [102]. Intracoronary bolus of
apelin-36leadstoincreasedcoronarybloodﬂowandreduced
peak and end-diastolic left ventricular pressures [102]. These
remarkable peripheral and coronary vasodilatation eﬀects
of apelin and also its eﬀect on cardiac output increase
shows apelin as a novel medication for the patients with
HF. Decreased density of apelin receptors in the heart tissues
withcardiomyopathymayblocktheinotropiceﬀectofapelin
on the heart [53]. APJ gene also has been suggested as a
modiﬁer gene for idiopathic dilated cardiomyopathy [103].
Furtherinvestigationsshouldfocusoncombinationofapelin
therapy with apelin receptor agonists. Synergetic eﬀects of
apelin with APJ agonists may increase the eﬃcacy of apelin
therapy for the patients with HF. However, these ﬁndings are
not consistent with Atluri et al. (2007) ﬁndings in rats [98].
Atluri et al. (2007) showed increased APJ protein levels in
myocardium of the rats with HF [98]. Pitkin et al. (2010)
suggested [Glp65,Nle75,Tyr77][125I]-apelin-13 as a potent
agent with high-aﬃnity, saturable and reversible aﬀectwhich
might reﬂect its therapeutic eﬃcacy in future [53].
The diﬀerence between APJ in myocardium and arterial
system of the HF patients is not completely deﬁned. Due
to the dual ionotropic and hypotensive eﬀects of apelin on
the patients with HF, we need to be cautious about the
application of this agent in the clinical setting. APJ agonist
drugs may increase the eﬃcacy of apelin therapy in the HF
patients; however it is not clear whether APJ agonist drugs
will increase the arterial hypotensive eﬀects of apelin. Exper-
imental evidence has established an association between Ang
IIanddevelopmentofHF[45,81].Chunetal.(2008)proved
that apelin signaling can antagonize Ang II actions in vascu-
lar disease by NO production and inhibiting Ang II cellular
signaling [104]. Generally, apelin modulates Ang II-induced
cardiovascular ﬁbrosis [105] which may be linked to apelin
ability to inhibit the plasminogen activator inhibitor type-1
production resulting in secondary changes in the expression
of matrix proteins and degrading enzymes [105]. Apelin-
13 inhibits Ang II-induced vascular contraction mainly
through NO-dependent pathways [106]. There is evidence
that apelin can be increased by blocking RAS [107]w h i c h
may contribute to AT1 blocker treatment in the clinical
setting [108]. This evidence led to the notion that apelin
therapy may ameliorate RAS-related HF aggravating eﬀects.
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